Pharmacologic class (EPC) · 2 drug pages

Hyperpolarization-activated cyclic nucleotide-gated channel blocker: adverse event reports filed with FDA

3,611 reports list a drug in this class as a suspect or interacting product, 2009–2026.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

3,611
reports across the class: 0% of all reports; 184
reports, 12 months to June 2026: 266 in the 12 months before; 56.9%
marked serious by the reporter: 57.4% across all reports; 2
drugs with a page: brand and generic names counted separately

Hyperpolarization-activated cyclic nucleotide-gated channel blocker is a pharmacologic class (an FDA Established Pharmacologic Class) with 2 drug pages on this site. Together those drugs are listed as a suspect or interacting product in 3,611 adverse event reports received by FDA, 0% of the database, from July 2009 to June 2026.

184 reports arrived in the 12 months to June 2026, down 31% from 266 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. 56.9% of the class's reports are marked serious, 7.1% record death among the outcomes and 26.6% record hospitalisation, as reported.

Across the class the reactions recorded most often are off label use (33%), hypotension (6.8%) and bradycardia (6.4%). The class median share shown beside each term is the middle value across the member drugs; it is the comparison used on every drug page in this class.

The members table is ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Drugs in the class

Drug	Name type	Reports	Latest 12 months	Marked serious	Top term recorded
CorlanorIvabradine	brand	1,845	36	25.1%	Off label use
Ivabradine	generic	1,766	148	90.1%	Off label use

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Reactions recorded across the class

share of class reports recording the termmedian drug in the class

Off label useused for a purpose or in a way not on the label33%1,191
Hypotensionlow blood pressure6.8%247
Bradycardiaslow heart rate6.4%231
Drug interactionan interaction between medicines5.6%201
Dizzinesslight-headedness or unsteadiness5.1%185
Dyspnoeashortness of breath5.1%184
Cardiac failureheart failure5.1%183
Drug ineffectivethe medicine did not work as expected4%143
Fatiguetiredness3.7%132
Palpitationsawareness of the heartbeat3.2%115
Chest painchest pain3.2%114
Syncopefainting2.5%91
Heart rate increaseda fast heart rate reading2.5%90
Oedema peripheralswelling of the legs, ankles or hands2.5%90
Headachehead pain2.3%84
Visual impairmentreduced vision2.3%82
Feeling abnormalfeeling odd or not right2.2%80
Electrocardiogram QT prolongeda QT prolongation on the ECG2.2%78
Photopsia2.2%78
Nauseafeeling sick2.1%77
Deaththe patient died; cause not stated by this term2.1%76
Angina pectoris2%71
Atrial fibrillationan irregular heart rhythm1.8%66
Tachycardiafast heart rate1.8%66
Heart rate decreased1.8%64

Solid bar: share of all class reports. Hollow bar: the median share across the 2 member drugs, the reference used on each member's page. One report can record several terms.

Outcomes, patients and reporters

Outcomes recorded

Death7.1%257

Life-threatening5.8%208

Hospitalisation (initial or prolonged)26.6%960

Disability2%72

Congenital anomaly0.6%20

Other serious43.3%1,563

Not serious43.1%1,557

Patient age

Under 20.7%24

2 to 110.3%12

12 to 171.6%58

18 to 4420.9%755

45 to 6423.3%842

65 to 7410%362

75 and over9.7%349

Age not given33.5%1,209

Who reported

Physician46.1%1,665

Pharmacist5.5%199

Other health professional24.7%892

Lawyer0%0

Consumer or non-health professional23.3%841

Not given0.4%14

Grey bar: all 20,646,523 reports in the database. Outcome flags are as the reporter set them and are not verified by FDA.

Questions about Hyperpolarization-activated cyclic nucleotide-gated channel blocker reports

Which drugs are in the Hyperpolarization-activated cyclic nucleotide-gated channel blocker class on this site?

Corlanor and Ivabradine. Class membership comes from the pharmacologic class (EPC) on the drug's FDA label.

How many reports does the class have?

3,611 reports through June 2026, 184 of them in the latest 12 months. A report listing two drugs of the class counts once for each.

What reactions are recorded most often?

off label use (33%), hypotension (6.8%), bradycardia (6.4%), drug interaction (5.6%) and dizziness (5.1%).

Can the members table be used to rank the drugs?

No. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." Drugs differ in how many people take them, in the conditions they treat, in time on the market and in how diligently reports are collected.

How do I report an adverse event?

Through FDA MedWatch (Form FDA 3500, or 1-800-FDA-1088) or to the manufacturer. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A class is the Established Pharmacologic Class most often attached to a drug's reports by openFDA's label harmonisation, or from the NDC Directory where reports carry none. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.